Patents Assigned to The Government of the USA, as represented by the Secretary, Department of Health & Human Services
-
Patent number: 11566268Abstract: Embodiments of the present invention are directed to processes for the production of (R)-3-hydroxybutyl (R)-3-hydroxybyrate. Poly (R)-3-hydroxybyrate is transesterified with an alcohol, to form a first ester portion and a second ester portion. The first ester portion is reduced to the diol to form a diol portion and the diol portion is reacted with the second ester portion to produce (R)-3-hydroxybutyl (R)-3-hydroxybyrate.Type: GrantFiled: March 14, 2014Date of Patent: January 31, 2023Assignees: GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Kieran Clarke, Richard Lewis Veech, M. Todd King
-
Patent number: 11311509Abstract: The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, esters of D-?-hydroxybutyrate, oligomers of D-?-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject.Type: GrantFiled: November 29, 2018Date of Patent: April 26, 2022Assignees: OXFORD UNIVERSITY INNOVATION LIMITED, Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Kieran Clarke, Richard Lewis Veech
-
Publication number: 20220105186Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.Type: ApplicationFiled: November 2, 2021Publication date: April 7, 2022Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the USA as Represented by the Secretary Department of Health and Human ServicesInventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
-
Patent number: 10821062Abstract: A method of protecting animal tissue particularly skin, from damage caused by radiation exposure, by contacting the tissue with a ketone ester, a method of protecting skin, reducing the deterioration of skin or maintaining or improving the properties of skin by applying topically to the skin a ketone body comprising (R)-3-hydroxybutyrate moieties is disclosed. A ketone body comprising (R)-3-hydroxybutyrate moieties, especially enantiomerically enriched R-1,3-hydroxybutyl-(R)-3-hydroxybutyrate, for such uses is also provided.Type: GrantFiled: September 16, 2013Date of Patent: November 3, 2020Assignees: TDELTAS LIMITED, GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICEInventors: Kieran Clarke, Richard Lewis Veech
-
Publication number: 20200188515Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.Type: ApplicationFiled: July 8, 2019Publication date: June 18, 2020Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the USA as Represented by the Secretary Department of Health and Human ServicesInventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
-
Publication number: 20160367658Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: September 6, 2016Publication date: December 22, 2016Applicants: The Government of the USA, as represented by the Secretary, Department of Health and Human Services, Mahidol UniversityInventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Publication number: 20140194509Abstract: A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.Type: ApplicationFiled: December 10, 2013Publication date: July 10, 2014Applicants: Government of the USA, as Represented by the Secretary, Department of Health and Human Services, Isis Innovation LimitedInventors: Kieran Clarke, Richard Lewis Veech
-
Publication number: 20140141040Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicants: Mahidol University, The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Publication number: 20130052226Abstract: The invention provides a codon-optimized parvovirus polynucleotide composition and methods of expressing this polynucleotide in a variety of mammalian cells, including non-erythroid progenitor cells, to produce immunogenic compositions.Type: ApplicationFiled: February 9, 2011Publication date: February 28, 2013Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human ServicesInventors: Ning Zhi, Neal S. Young, Sachiko Kajigaya
-
Publication number: 20130011433Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: ApplicationFiled: November 28, 2011Publication date: January 10, 2013Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
-
Publication number: 20120328640Abstract: The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3?/CCL20 or ?-defensin mDF2?. The invention further provides cancer vaccines and methods for treating subjects having, or at risk of developing, cancer.Type: ApplicationFiled: August 16, 2012Publication date: December 27, 2012Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human ServicesInventors: Bira Arya, Dan Longo, Igor Espinoza
-
Publication number: 20120282701Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.Type: ApplicationFiled: July 17, 2012Publication date: November 8, 2012Applicant: Government of the USA, as Represented by the Secretary, Department of Health and Human ServicesInventors: DENNIS J. KOPECKO, MANUEL OSORIO, SIBA BHATTACHARYYA, CHANDRAKANT P. GIRI, MILAN BLAKE
-
Publication number: 20120277286Abstract: The present invention features compositions and methods for the treatment or prevention of diseases associated with a mitochondrial defect.Type: ApplicationFiled: May 1, 2012Publication date: November 1, 2012Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human ServicesInventors: Richard J. Youle, Derek Narendra, Der-Fen Suen
-
Publication number: 20120201907Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: April 13, 2012Publication date: August 9, 2012Applicants: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Johns Hopkins University, The Regents of the University of California, Government of the USA represented by the Secretary of the Department of Health and Human ServicesInventors: David A. WINK, Martin FEELISCH, David A. KASS, Nazareno PAOLOCCI, Katrina MIRANDA, Jon FUKUTO, Tatsuo KATORI
-
Publication number: 20120114694Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.Type: ApplicationFiled: September 22, 2011Publication date: May 10, 2012Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney
-
Publication number: 20120107358Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.Type: ApplicationFiled: September 23, 2011Publication date: May 3, 2012Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human ServicesInventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
-
Publication number: 20100029547Abstract: The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, Microcystis viridis, which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1?6)Man-beta (1?4) GlcNAc-beta(1?4)GlcNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also relates to an isolated polypeptide comprising one or more copies of the sequence GPLWSNXEAQXXGPX (SEQ ID NO: 1) and/or one or more copies of the sequence FTGQWXTXVEXXMSV (SEQ ID NO: 2), wherein the polypeptide binds specifically to the above-mentioned oligosaccharide. Conjugates comprising such polypeptides and an effector molecule are also disclosed, as are methods of using such polypeptides or conjugates, e.g., for inhibiting infection by a virus, such as HIV, or for removing a virus, such as HIV, from a sample, such as a bodily fluid or an inanimate object.Type: ApplicationFiled: March 9, 2005Publication date: February 4, 2010Applicant: The Government of the USA as represented by the Secretary, Department of Health and Human ServicesInventor: Carole A. Bewley
-
Publication number: 20080226559Abstract: Disclosed are benztropine analogs having the formula (I) in which Ar is a C6-C20 monocyclic aryl group or a C10-C20>bicyclic aryl group or a heteroaryl, heterocyclic, or arylheterocyclic group having 2 to 12 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, P, and any combination thereof; m=1 to 5; n=1 to 3; and R1 to R4 are as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e.g., in treating mental disorders.Type: ApplicationFiled: August 24, 2006Publication date: September 18, 2008Applicant: GOVERNMENT OF THE USA,REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Amy Hauck Newman, Mu-Fa Zou, Jonathan L. Katz
-
Publication number: 20070087356Abstract: The invention provides a microarray and methods for producing a protein microarray. The array comprises multiple nucleic acid molecules immobilized on a substrate, each comprising (i) a protein-binding domain and (ii) a nucleic acid sequence encoding a fusion protein comprising a polypeptide of interest and a DNA-binding protein that binds the protein-binding domain, and one or more fusion proteins produced from the multiple nucleic acid molecules. Each fusion protein is immobilized on the substrate via binding to a nucleic acid sequence comprising the protein-binding domain present on the nucleic acid molecule from which the fusion protein is produced or on the substrate. The invention also provides a method of analyzing protein interactions with, for example, other proteins, lipids and drugs.Type: ApplicationFiled: October 19, 2005Publication date: April 19, 2007Applicant: Government of the USA, represented by the Secretary, Department of Health & Human ServicesInventors: Deb Chatterjee, Kalavathy Sitaraman, James Hartley, Cassio Baptista, David Munroe
-
Publication number: 20070048860Abstract: The present invention relates to novel modified CEA agonist (or antagonist) peptides, polypeptides and proteins containing a modified epitope therein, nucleic acids coding therefor, vectors comprising said nucleic acids, mixtures and compositions of the aforementioned agents, and their advantageous use in generating CEA-specific immune responses and/or in the treatment of cancers and the present invention further relates to the foregoing combined with one or more costimulatory molecules.Type: ApplicationFiled: December 30, 2005Publication date: March 1, 2007Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey Schlom, James Hodge, Sam Zaremba, Maria Salazar